Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In...
Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In...
辉瑞表示，将在2024年第二季度启动一项多年度计划，以降低我们的商品销售成本；降低商品销售成本的多年计划的第一阶段预计将在2027年底之前节省约15亿美元；成本将主要记录在...
Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In 2024, With Cash Outlays Expected In 2025 And 2026; One-Time Costs To Achieve Savings Associated With First Phase Of Program Are Expected To Be About $1.7B
辉瑞表示，将在2024年第二季度启动一项多年度计划，以降低我们的商品销售成本；降低商品销售成本的多年计划的第一阶段预计将在2027年底之前节省约15亿美元；成本将主要记录在2024年，现金支出预计在2025年和2026年；实现与第一阶段计划相关的节省的一次性成本预计约为17亿美元
- Reuters
-路透社
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。